KRRO NASDAQ
Korro Bio, Inc.
1W: +40.9%
1M: +39.9%
3M: +32.1%
YTD: +65.2%
1Y: -65.1%
3Y: +6.4%
5Y: -96.1%
$13.30
+1.28 (+10.65%)
Pre-Market: $13.52 (+0.22, +1.65%)
Weekly Expected Move ±17.9%
$8
$10
$12
$14
$16
Credit Risk of going bust: higher than 95% of companies Debt: 17.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.87 (down 93%), Korro Bio, Inc. would be worth roughly what it owes.
Total debt $42.2M against a stock market value of $195.9M.
Distance to default 0.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $21.1M (short-term plus half of long-term), stock volatility 179.9%; Altman Z'' -5.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.87 (down 93%), Korro Bio, Inc. would be worth roughly what it owes.
Total debt $42.2M against a stock market value of $195.9M.
Distance to default 0.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $21.1M (short-term plus half of long-term), stock volatility 179.9%; Altman Z'' -5.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.60
Bullish
2 bullish
1 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (38)
Korro Bio (NASDAQ:KRRO) Major Shareholder Lynx1 Capital Management Lp Buys 25,124 Shares of Stock
Korro Bio (NASDAQ:KRRO) Major Shareholder Lynx1 Capital Management Lp Acquires 52,175 Shares of Stock
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of “Moderate Buy” by Brokerages
BlackRock Inc. Takes Position in Korro Bio, Inc. $KRRO
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Moderate Buy” by Analysts
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro to Participate in Upcoming Investor Conferences
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Korro Bio (NASDAQ:KRRO) Stock Price Down 0.8% – Should You Sell?
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?
JPMorgan Chase & Co. Buys 196,079 Shares of Korro Bio, Inc. $KRRO
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of “Moderate Buy” by Brokerages
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
12 Health Care Stocks Moving In Friday's Pre-Market Session
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
12 Health Care Stocks Moving In Thursday's After-Market Session
Korro Bio GAAP EPS of -$12.48 misses by $3.43, revenue of $6.4M beats by $1M
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
Korro announces oversubscribed $85 million private placement
Korro Announces Oversubscribed $85 Million Private Placement
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Korro to Host Virtual Analyst Day on January 27, 2026
Korro Bio (NASDAQ:KRRO) Shares Down 5.9% – Here’s What Happened
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts